Currently the FDA categorizes psychedelics such as LSD and psilocybin as Schedule I drugs, indicating that these substances have no medical benefits. Despite this classification, a resurgence of research has demonstrated therapeutic benefits of psychedelics for treatment of psychiatric disorders. These exciting findings have resulted in a paradigm shift for treatment-resistant psychiatric conditions, along with increased public interest and efforts to legalize psychedelics for medicinal use. This virtual conversation will bring together leading scientists in the fields of pharmacology, neuroscience, and psychiatry to discuss how psychedelics work in the brain to produce therapeutic benefits for depression and other mood disorders. The role of psychotherapy in tandem with the psychedelic experience will also be explored.